Total Payments
$3,956
2024 Payments
$2,091
Companies
24
Transactions
84
Medicare Patients
1,810
Medicare Billing
$166,560
Payment Breakdown by Category
Food & Beverage$2,536 (64.1%)
Research$1,412 (35.7%)
Education$8.45 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,536 | 72 | 64.1% |
| Unspecified | $1,412 | 11 | 35.7% |
| Education | $8.45 | 1 | 0.2% |
Payments by Type
General
$2,545
73 transactions
Research
$1,412
11 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $1,426 | 13 | $0 (2024) |
| Amgen Inc. | $389.70 | 6 | $0 (2023) |
| Novo Nordisk Inc | $381.69 | 10 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $235.32 | 5 | $0 (2023) |
| Lilly USA, LLC | $217.62 | 9 | $0 (2024) |
| Dexcom, Inc. | $138.65 | 6 | $0 (2024) |
| IBSA Pharma Inc. | $122.21 | 1 | $0 (2023) |
| Ascensia Diabetes Care Us Inc. | $113.07 | 6 | $0 (2024) |
| Insulet Corporation | $104.70 | 4 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $103.35 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,091 | 41 | ABBVIE INC. ($1,407) |
| 2023 | $818.62 | 20 | Amgen Inc. ($145.70) |
| 2022 | $344.92 | 16 | Lilly USA, LLC ($125.56) |
| 2019 | $202.75 | 2 | Amgen Inc. ($202.75) |
| 2018 | $313.46 | 3 | SANOFI-AVENTIS U.S. LLC ($117.14) |
| 2017 | $185.97 | 2 | Alexion Pharmaceuticals, Inc. ($103.35) |
All Payment Transactions
84 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $23.65 | General |
| Category: Diabetes Care | ||||||
| 12/11/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $8.34 | General |
| Category: Diabetes | ||||||
| 11/22/2024 | BETA BIONICS, INC. | iLet Bionic Pancreas (Device), iLet Bionic Pancreas, iLet Bionic Pancreas | Food and Beverage | In-kind items and services | $50.75 | General |
| Category: Automated insulin delivery system | ||||||
| 11/11/2024 | Insulet Corporation | Omnipod (Device) | Food and Beverage | Cash or cash equivalent | $15.81 | General |
| Category: Insulin Pump | ||||||
| 11/08/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $13.07 | General |
| Category: Endocrinology | ||||||
| 09/30/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $19.90 | General |
| Category: Diabetes | ||||||
| 09/25/2024 | Amphastar Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $15.73 | General |
| 09/10/2024 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $19.87 | General |
| Category: Diabetes | ||||||
| 08/27/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $20.54 | General |
| Category: Endocrinology | ||||||
| 08/21/2024 | Eli Lilly and Company | — | — | In-kind items and services | $31.46 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | ||||||
| 08/13/2024 | Ascensia Diabetes Care Us Inc. | EVERSENSE E3 SENSOR KIT - RETAIL (Device) | Food and Beverage | In-kind items and services | $24.43 | General |
| Category: Diabetes | ||||||
| 08/01/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $4.10 | General |
| Category: Diabetes | ||||||
| 07/23/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $13.50 | General |
| Category: Diabetes | ||||||
| 07/08/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $21.53 | General |
| Category: Diabetes Care | ||||||
| 06/27/2024 | Ascensia Diabetes Care Us Inc. | EVERSENSE E3 SENSOR KIT - RETAIL (Device) | Food and Beverage | In-kind items and services | $14.26 | General |
| Category: Diabetes | ||||||
| 06/17/2024 | Ascensia Diabetes Care Us Inc. | EVERSENSE E3 SENSOR KIT - RETAIL (Device) | Food and Beverage | In-kind items and services | $16.27 | General |
| Category: Diabetes | ||||||
| 06/01/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $111.71 | General |
| 05/23/2024 | BETA BIONICS, INC. | iLet Bionic Pancreas (Device), iLet Bionic Pancreas, iLet Bionic Pancreas | Food and Beverage | In-kind items and services | $17.42 | General |
| Category: Automated insulin delivery system | ||||||
| 05/07/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $33.23 | General |
| Category: Diabetes | ||||||
| 05/06/2024 | Medtronic, Inc. | MINIMED 780G (Device) | Food and Beverage | In-kind items and services | $30.96 | General |
| Category: Durable Pump | ||||||
| 04/18/2024 | Amneal Pharmaceuticals LLC | UNITHROID (Drug) | Food and Beverage | In-kind items and services | $30.00 | General |
| Category: ENDOCRINOLOGY | ||||||
| 04/12/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $586.23 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/12/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $69.00 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/12/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $50.54 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/12/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $37.50 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism | ABBVIE INC. | $1,380 | 10 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | Eli Lilly and Company | $31.46 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 765 | 2,428 | $271,013 | $83,120 |
| 2022 | 9 | 451 | 597 | $111,781 | $36,753 |
| 2021 | 7 | 239 | 321 | $84,057 | $19,529 |
| 2020 | 8 | 355 | 469 | $121,178 | $27,157 |
Total Patients
1,810
Total Services
3,815
Medicare Billing
$166,560
Procedure Codes
41
All Medicare Procedures & Services
41 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 220 | 351 | $96,968 | $30,647 | 31.6% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 15 | 1,260 | $69,590 | $23,072 | 33.2% |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | Office | 2023 | 107 | 260 | $35,630 | $10,570 | 29.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 29 | 33 | $12,246 | $4,057 | 33.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 53 | 60 | $11,292 | $3,828 | 33.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 31 | 31 | $12,751 | $3,272 | 25.7% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 57 | 110 | $14,416 | $2,888 | 20.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 142 | 174 | $3,038 | $1,455 | 47.9% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 14 | 14 | $4,618 | $1,399 | 30.3% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 82 | 117 | $7,179 | $1,106 | 15.4% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 15 | 18 | $3,285 | $826.45 | 25.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 135 | 189 | $49,617 | $17,886 | 36.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 63 | 63 | $23,835 | $7,642 | 32.1% |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | Office | 2022 | 58 | 113 | $14,929 | $4,772 | 32.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 16 | 17 | $6,005 | $2,166 | 36.1% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2022 | 43 | 59 | $7,552 | $1,600 | 21.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 16 | 18 | $3,188 | $1,259 | 39.5% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2022 | 12 | 12 | $2,148 | $694.60 | 32.3% |
| 83036 | Hemoglobin a1c level | Office | 2022 | 49 | 55 | $3,300 | $524.33 | 15.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 59 | 71 | $1,207 | $209.01 | 17.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 59 | 74 | $21,978 | $6,507 | 29.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 51 | 66 | $19,602 | $4,227 | 21.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 23 | 50 | $10,100 | $2,743 | 27.2% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 23 | 28 | $8,988 | $1,832 | 20.4% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 29 | 30 | $9,630 | $1,442 | 15.0% |
About Dr. Sahzene Yavuz, MD
Dr. Sahzene Yavuz, MD is a Internal Medicine healthcare provider based in Sayre, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/27/2009. The National Provider Identifier (NPI) number assigned to this provider is 1003054248.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sahzene Yavuz, MD has received a total of $3,956 in payments from pharmaceutical and medical device companies, with $2,091 received in 2024. These payments were reported across 84 transactions from 24 companies. The most common payment nature is "Food and Beverage" ($2,536).
As a Medicare-enrolled provider, Yavuz has provided services to 1,810 Medicare beneficiaries, totaling 3,815 services with total Medicare billing of $166,560. Data is available for 4 years (2020–2023), covering 41 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Diabetes & Metabolism|Endocrinology, Diabetes & Metabolism
- Location Sayre, PA
- Active Since 01/27/2009
- Last Updated 04/20/2024
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1003054248
Products in Payments
- ARMOUR THYROID (Drug) $1,380
- EVENITY (Biological) $268.87
- MOUNJARO (Drug) $140.72
- Dexcom G6 Transmitter (Medical Supply) $138.65
- Tirosint (Drug) $122.21
- Prolia (Biological) $120.83
- SOLIQUA 100/33 (Biological) $118.18
- SOTAGLIFLOZIN (Drug) $117.14
- Omnipod (Device) $104.70
- Strensiq (Drug) $103.35
- Victoza (Drug) $103.14
- iLet Bionic Pancreas (Device) $102.14
- Tymlos (Biological) $93.18
- MINIMED 780G (Device) $89.51
- t:slim X2 Insulin Pump with Control-IQ (Device) $88.01
- CABOMETYX (Drug) $87.32
- Ozempic (Drug) $84.22
- JARDIANCE (Drug) $82.13
- EVERSENSE E3 SENSOR KIT - RETAIL (Device) $73.95
- FREESTYLE LIBRE 3 (Device) $45.18
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Sayre
Jedediah Mcclintic, Md, MD
Internal Medicine — Payments: $9,824
Internal Medicine $9,824
Subash Ghimire, M.d, M.D
Internal Medicine — Payments: $2,815
Internal Medicine $2,815
Tsujung Yang
Internal Medicine — Payments: $2,502
Internal Medicine $2,502
Rajamurugan Meenakshisundaram, Md, MD
Internal Medicine — Payments: $1,712
Internal Medicine $1,712
Dr. Michael Depersis, D.o, D.O
Internal Medicine — Payments: $1,655
Internal Medicine $1,655
Dr. Eric Macapinlac, Md, MD
Internal Medicine — Payments: $1,064
Internal Medicine $1,064